Core Insights - The company reported significant growth in both revenue and net profit for the third quarter of 2025, with a revenue of 201 million yuan, representing a year-on-year increase of 41.49% [1] - The net profit attributable to shareholders reached 27.21 million yuan, showing a remarkable year-on-year growth of 719.47% [1] - For the first three quarters of 2025, the company achieved a total revenue of 692 million yuan, which is a 51.86% increase compared to the same period last year [1] - The net profit for the first three quarters was 65.22 million yuan, reflecting an impressive year-on-year growth of 985.18% [1] - The sales revenue from traditional Chinese medicine products saw a significant increase during the reporting period [1]

关于第六届董事会第四次会议决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、董事会会议召开情况 特一药业集团股份有限公司（以下简称"公司"）第六届董事会第四次会议于 2025 年 10 月 23 日 9:30 在公司会议室采用现场及电子通信方式召开，会议通知于 2025 年 10 月 21 日以电子邮件方式发出。本次会议由董事长许荣煌主持，应出席董事 6 名，实际 出席 6 名，其中卢北京、赵晓波、赖瀚琪等 3 名董事以电子通信表决方式出席会议。公 司非董事高级管理人员列席了本次会议。会议的召集、召开符合《公司法》和《公司章 程》的相关规定。 二、董事会会议审议情况 具体内容详见公司同日刊登在巨潮资讯网（www.cninfo.com.cn）的《2025 年第三 季度报告》。 公司 2025 年第三季度财务信息已由公司审计委员会审议并取得了全体委员明确同 意的意见。 证券代码：002728 证券简称：特一药业 公告编号：2025-062 特一药业集团股份有限公司 1、审议通过《关于审议公司 2025 年第三季度报告的议案》 特此公告。 特一药业集 ...

特一药业集团股份有限公司 2025 年第三季度报告 3.第三季度财务会计报告是否经过审计 证券代码：002728 证券简称：特一药业 公告编号：2025-061 特一药业集团股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会及董事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担 个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 □是 ☑否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 ☑否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 200,707,722.19 | 41.49% | 691,850,596.25 | 51.86% | | 归属 ...

Market Overview - The Chinese medicine sector experienced a decline of 0.34% on October 23, with Zhongsheng Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3922.41, up 0.22%, while the Shenzhen Component Index closed at 13025.45, also up 0.22% [1] Stock Performance - Notable gainers included: - Qidi Pharmaceutical (Code: 000590) with a closing price of 12.68, up 9.97% and a trading volume of 261,000 shares, totaling 320 million yuan [1] - Zhendong Pharmaceutical (Code: 300158) closed at 7.32, up 4.27% with a trading volume of 1,012,600 shares, totaling 753 million yuan [1] - Major decliners included: - Zhongsheng Pharmaceutical (Code: 002317) closed at 18.43, down 4.75% with a trading volume of 569,600 shares, totaling 1.056 billion yuan [2] - Darentang (Code: 600329) closed at 43.15, down 3.68% with a trading volume of 75,800 shares, totaling 328 million yuan [2] Capital Flow - The Chinese medicine sector saw a net outflow of 897 million yuan from institutional investors, while retail investors contributed a net inflow of 989 million yuan [2] - The table of capital flow indicates that: - Qidi Pharmaceutical had a net inflow of 23.93 million yuan from institutional investors, while retail investors had a net outflow of 25.84 million yuan [3] - Zhendong Pharmaceutical experienced a net inflow of 19.97 million yuan from institutional investors, with retail investors seeing a net outflow of 2.25 million yuan [3]

Group 1 - The trading volume of Te Yi Pharmaceutical reached 1.218 billion yuan, marking a new high since December 8, 2023 [2] - The latest stock price decreased by 2.25%, with a turnover rate of 28.64% [2] - The previous trading day's total transaction volume for the stock was 1.201 billion yuan [2]

Market Overview - On October 22, the trading volume of the Shanghai and Shenzhen stock markets reached 1.67 trillion, a decrease of 224.8 billion compared to the previous trading day [1] - Sectors that saw significant gains included deep earth economy concepts, plant-based meat, wind power equipment, and real estate, while precious metals and battery sectors experienced declines [1] Stock Performance - High-performing stocks included Dayou Energy with 9 consecutive trading limits, *ST Nan Zhi with 9 days of gains, and *ST Wan Fang with 8 days of gains [3] - The top three net purchases on the daily leaderboard were Keri Technology, Asia-Pacific Pharmaceutical, and Marco Polo, with net purchases of 140 million, 127 million, and 90.2 million respectively [3] Institutional Activity - The top three net sales on the daily leaderboard were Hezhu Intelligent, Haima Automobile, and Deshi Co., with net sales of 118 million, 99.5 million, and 96.2 million respectively [4] - Among stocks involving institutional special seats, the top three net purchases were Rongxin Culture, Kebo Da, and Te Yi Pharmaceutical, with net purchases of 111 million, 41.7 million, and 39.1 million respectively [4] Company Highlights Keri Technology - Positioned as a provider of mid-to-late stage solutions for lithium battery manufacturing equipment, the company has seen significant growth in its XR/VR testing equipment, which has been shipped in bulk to leading clients [5] - For the first half of the year, the company reported revenue of 1.106 billion and a net profit of 123 million, with revenue growth of 6.31% and net profit growth of 37.28% year-on-year, indicating notable performance improvement [6] Asia-Pacific Pharmaceutical - Announced a change in control with the major shareholder, Fubon Group, planning to transfer 14.62% of shares to Xinghao Holdings at 8.26 yuan per share, totaling 900 million [7] - The company plans to raise up to 700 million through a private placement to fund the development of oncolytic virus drugs and long-acting complex formulations, transitioning from traditional generics to improved new drugs and innovative drugs [7] Hezhu Intelligent - Recently won a bid for the fusion energy BEST vacuum chamber project worth 209 million and is forming a specialized team to tackle core components of fusion reactors [9] - The company's color sorting machines account for 57% of its revenue, with 20-25% of this business coming from exports, maintaining a strong position in the domestic market [9] Key Trading Stocks - Rongxin Culture saw a 3.56% increase with a turnover rate of 45.97% and a total transaction volume of 809 million, with institutional net purchases of 111 million [10] - Sanwei Communication increased by 5.00% with a turnover rate of 33.08% and a total transaction volume of 3.005 billion, with institutional net purchases of 23 million [10] - Te Yi Pharmaceutical hit the daily limit with a turnover rate of 30.11% and a total transaction volume of 1.201 billion, with institutional net purchases of 39.1 million [10]

证券日报网讯 10月22日晚间，特一药业发布公告称，公司股票连续三个交易日内（2025年10月20日、 2025年10月21日、2025年10月22日）收盘价格涨幅偏离值累计超过20%，属于股票交易异常波动的情 况。经核实，公司经营正常，已披露的经营情况、内外部经营环境未发生重大变化；公司前期所披露的 信息，不存在需要更正、补充之处；公司未发现近期公共传媒报道了可能或已经对公司股票交易价格产 生较大影响的未公开重大信息。 （编辑 任世碧） ...

Group 1: Market Overview - The total trading volume of the Shanghai and Shenzhen Stock Connect today reached 213.79 billion, with Cambricon and Zhongji Xuchuang leading in trading volume for Shanghai and Shenzhen stocks respectively [1] - The Shanghai Stock Connect had a total trading amount of 105.13 billion, while the Shenzhen Stock Connect totaled 108.67 billion [2] Group 2: Top Stocks by Trading Volume - In the Shanghai Stock Connect, Cambricon (688256) topped the trading volume with 2.768 billion, followed by Industrial Fulian (601138) at 2.505 billion and Sanfang (601899) at 2.082 billion [3] - In the Shenzhen Stock Connect, Zhongji Xuchuang (300308) led with 3.374 billion, followed by CATL (300750) at 2.491 billion and Xinyi Technology (300502) at 2.278 billion [3] Group 3: Sector Performance - The oil and gas sector saw the highest net inflow of funds, amounting to 454 million, while the electronic sector experienced the largest net outflow of 8.775 billion [4][6] - Other sectors with notable net inflows included household appliances (301 million) and building materials (293 million) [5] Group 4: ETF Trading - The top ETF by trading volume was the Gold ETF (518880) with 12.694 billion, followed by the Hong Kong Securities ETF (513090) at 9.949 billion [9][10] - The French CAC40 ETF (513080) saw a remarkable increase in trading volume, growing by 486% compared to the previous trading day [11] Group 5: Futures Market - In the futures market, all major contracts (IH, IF, IC, IM) saw a reduction in both long and short positions, with the short positions decreasing more significantly [12] Group 6: Institutional Activity - Notable institutional buying included Rongxin Culture with 117 million and Te Yi Pharmaceutical with 39.09 million, while significant selling was observed in Blue Feng Biochemical with 73.54 million [13][14] - The overall activity from institutions was relatively low, with limited buying and selling across various stocks [13][16]

Core Insights - The NMN concept index rose by 0.95%, ranking 10th among concept sectors, with 18 stocks increasing in value, led by Te Yi Pharmaceutical, which hit the daily limit, and other notable gainers including Su Yan Jing Shen, Zhong Sheng Pharmaceutical, and Shuanglu Pharmaceutical, which rose by 5.93%, 5.22%, and 4.42% respectively [1][2] Market Performance - The NMN concept sector saw a net inflow of 181 million yuan from main funds, with 13 stocks receiving net inflows, and 5 stocks exceeding 10 million yuan in net inflow. Te Yi Pharmaceutical topped the list with a net inflow of 215 million yuan, followed by Zhong Sheng Pharmaceutical, De Zhan Health, and Shuanglu Pharmaceutical with net inflows of 51.31 million yuan, 35.94 million yuan, and 14.18 million yuan respectively [2][3] Fund Flow Ratios - Te Yi Pharmaceutical, Yaben Chemical, and De Zhan Health had the highest net inflow ratios, with rates of 17.90%, 11.09%, and 9.59% respectively [3]

证券代码：002728 证券简称：特一药业 公告编号：2025-060 特一药业集团股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 特一药业集团股份有限公司（以下简称"公司"；证券简称：特一药业；证券代码： 002728）股票连续三个交易日内（2025 年 10 月 20 日、2025 年 10 月 21 日、2025 年 10 月 22 日）收盘价格涨幅偏离值累计超过 20%。根据深圳证券交易所的相关规定，属于股 票交易异常波动的情况。 二、公司关注并核实的相关情况 针对公司股票交易异常波动，公司董事会对公司、控股股东及实际控制人就相关事 项进行了核实，现就有关情况说明如下： 4、公司、控股股东和实际控制人不存在关于本公司的应披露而未披露的重大事项， 不存在处于筹划阶段的重大事项。 5、公司控股股东、实际控制人在股票异常波动期间不存在买卖公司股票的情形。 三、是否存在应披露而未披露信息的说明 本公司董事会确认，本公司目前没有任何根据深交所《股票上市规则》等有关规定 应予以披露而未披露的事项或 ...